Two Sigma Advisers
PRME icon

Two Sigma Advisers’s Prime Medicine PRME Stock Holding History

Two Sigma Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-383,500
Closed -$1.33M – 1620
2025
Q4 		$1.33M Buy
+383,500
New +$1.71M ﹤0.01% 1342
2025
Q2 		– Sell
-53,900
Closed -$107K – 2491
2025
Q1 		$107K Buy
53,900
+10,700
+25% +$27.3K ﹤0.01% 2232
2024
Q4 		$126K Sell
43,200
-76,700
-64% -$269K ﹤0.01% 2192
2024
Q3 		$464K Sell
119,900
-56,600
-32% -$262K ﹤0.01% 1741
2024
Q2 		$907K Buy
176,500
+12,500
+8% +$75.8K ﹤0.01% 1595
2024
Q1 		$1.15M Buy
164,000
+118,000
+257% +$895K ﹤0.01% 1518
2023
Q4 		$408K Buy
+46,000
New +$354K ﹤0.01% 1997

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Two Sigma Advisers's PRME Position: Q1 2026 in Review

Two Sigma Advisers sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 383,500 shares — an estimated $1.33M sold.

Two Sigma Advisers first reported a position in PRME in Q4 2023 and held it in 7 quarters. The position peaked at $1.33M in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Two Sigma Advisers reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 383,500 Prime Medicine shares in Q1 2026, an estimated $1.33M.
  • Two Sigma Advisers first reported a position in Prime Medicine in Q4 2023 and held it in 7 quarters.
  • Two Sigma Advisers's Prime Medicine position peaked at $1.33M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.